2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-155654
    SARS-CoV-2 Mpro-IN-10
    		Inhibitor
    SARS-CoV-2 Mpro-IN-10 (27h) is a potent Mpro inhibitor with IC50 value and EC50 values of 10.9 nM and 43.6 nM, respectively. SARS-CoV-2 Mpro-IN-10 can be used for the research of SARS-CoV-2 virus.
    SARS-CoV-2 Mpro-IN-10
  • HY-151278
    SARS-CoV-2-IN-30
    		Inhibitor
    SARS-CoV-2-IN-30 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 exhibits antiviral activity with IC50s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 induces liposomal membrane disruption with an EC50 value of 6.9 μM.
    SARS-CoV-2-IN-30
  • HY-P990816
    Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29)
    		Inhibitor
    Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) reacts with the N-terminal domain (NTD) in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) can be used for the detections of flow cytometry and ELISA in SARS-CoV-2 infection.
    Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29)
  • HY-162777
    SARS-CoV-2-IN-93
    		Inhibitor
    SARS-CoV-2-IN-93 (compound 24) is an inhibitor of SARS-CoV-2 and HCoV-OC43. SARS-CoV-2-IN-93 can be used in antiviral research.
    SARS-CoV-2-IN-93
  • HY-162924
    SARS-CoV-IN-6
    		Inhibitor
    SARS-CoV-IN-6 (Compound 17) is an inhibitor of SARS-CoV-1 and SARS-CoV-2 RdRp, with an IC50 value of 7.8 μM against SARS-CoV-2 RdRp. SARS-CoV-IN-6 reduces cytopathic effects in cells infected with SARS-CoV-1 and SARS-CoV-2 replicon-based single-round infectious particles (SRIPs), and inhibits SARS-CoV N protein expression, with EC50 values of 0.12 µM for SARS-CoV-1 replicon-based SRIPs and 1.47 µM for SARS-CoV-2 replicon-based SRIPs.
    SARS-CoV-IN-6
  • HY-150625
    SARS-CoV-2 nsp13-IN-4
    		Inhibitor
    SARS-CoV-2 nsp13-IN-4 (C4 (d)) is a potent and selective nsp13 helicase small-molecule inhibitor and inhibit the ssDNA+ ATPase activity of nsp13 with an IC50 value of 57 μM. SARS-CoV-2 nsp13-IN-4 is agentlike molecule with molecular weight of less than 450Da and can provide a broad-spectrum antiviral effect.
    SARS-CoV-2 nsp13-IN-4
  • HY-147845
    F8-S40
    		Inhibitor
    F8-S40 is an inhibitor of SARS-CoV-2 main protease, with an IC50 of 10.88 μM.
    F8-S40
  • HY-144647
    SP inhibitor 1
    		Inhibitor
    SP inhibitor 1 (compound 34) is a selective SARS-CoV-2 spike protein (SP) inhibitor with an IC50 of 3.26 μM, >25 μM, >25 μM for SP, Mpro and PLpro protein, respectively. SP inhibitor 1 is a vitro SARS-CoV-2 replication inhibitor at non-toxic concentrations (0.3250<5.98 μM). SP inhibitor 1 shows cellular antiviral activity.
    SP inhibitor 1
  • HY-176264
    DNDI-6510
    		Inhibitor
    DNDI-6510 (Compound (S)-x38) is a non-covalent SARS-CoV-2 MPro inhibitor with a IC50 of 0.04 μM. DNDI-6510 has a potent antiviral activity across SARS-CoV-2 and its variants as well as a weak efficacy to SARS-CoV-1. DNDI-6510 significantly improves drug exposure in metabolically humanized mice model (8HUM).
    DNDI-6510
  • HY-157966
    SARS-CoV-2 3CLpro-IN-23
    		Inhibitor
    SARS-CoV-2 3CLpro-IN-23 (Compound Cd3) is a compound that can be isolated from Citrus depressa. SARS-CoV-2 3CLpro-IN-23 has good inhibitory activity to the SARS-CoV-2 spike protein, with KD of 0.79 μM. SARS-CoV-2 3CLpro-IN-23 can bind to key amino acid residue, disrupting the formation of the spike protein and h-ACE2 complex.
    SARS-CoV-2 3CLpro-IN-23
  • HY-10241S
    Simeprevir-13C,d3
    		Inhibitor
    Simeprevir-13C,d3 is the 13C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses.
    Simeprevir-<sup>13</sup>C,d<sub>3</sub>
  • HY-157477
    SARS-CoV-2 3CLpro-IN-22
    		Inhibitor
    SARS-CoV-2 3CLpro-IN-22 (Compound 17) is a cathepsin L (CTSL ) inhibitor with an IC50 value of 32.5 nM. SARS-CoV-2 3CLpro-IN-22 can be used for the study of SARS-CoV-2 virus.
    SARS-CoV-2 3CLpro-IN-22
  • HY-150623
    SARS-CoV-2 nsp13-IN-2
    		Inhibitor
    SARS-CoV-2 nsp13-IN-2 (Compound C2) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an IC50 of 42 μM against nsp13 ssDNA+ ATPase.
    SARS-CoV-2 nsp13-IN-2
  • HY-170515A
    (E),(Z)-RNF5 agonist 1
    		Inhibitor
    (E),(Z)-RNF5 agonist 1 (Compound Analog-1) is a RNF5 agonist that can enhance the ubiquitination and degradation of SARS-CoV-2 E protein by RNF5. (E),(Z)-RNF5 agonist 1 effectively inhibits the replication of SARS-CoV-2 and significantly alleviates pulmonary pathological damage and systemic inflammatory response in mouse infection models. (E),(Z)-RNF5 agonist 1 has a strong cytotoxic effect on neuroblastoma and melanoma. (E),(Z)-RNF5 agonist 1 can be used for research on anti-cancer and anti-viral purposes.
    (E),(Z)-RNF5 agonist 1
  • HY-155187
    SARS-CoV-2 3CLpro-IN-20
    		Inhibitor
    SARS-CoV-2 3CLpro-IN-20 (Compound 5g) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.43 μM, Ki: ?0.33?μM).
    SARS-CoV-2 3CLpro-IN-20
  • HY-17430R
    Amprenavir (Standard)
    		Inhibitor
    Amprenavir (Standard) is the analytical standard of Amprenavir. This product is intended for research and analytical applications. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.
    Amprenavir (Standard)
  • HY-P10804
    PIH
    		Inhibitor
    PIH is an antiviral peptide that effectively inhibits the HR1/HR2-mediated membrane fusion between MERS-CoV and host cells, with an IC50 of 1.171 μM. By forming a complex with gold nanorods (AuNRs), the antiviral efficacy of PIH can be further enhanced by 10-fold.
    PIH
  • HY-14768A
    Favipiravir sodium
    Favipiravir (T-705) sodium is an inhibitor of viral RNA polymerase (RNA polymerase), which is converted into its active form Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the activity of influenza virus RNA-dependent RNA polymerase (RdRP) with an IC50 of 341 nM.
    Favipiravir sodium
  • HY-138794G
    XL177A (GMP)
    		Inhibitor
    XL177A GMP is XL177A (HY-138794) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7. XL177A destabilizes non-canonical PRC1 complexes or KDM6A and reduces chromatin deposition of H2AK119Ub, thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7-nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin. XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC-mutated colorectal cancer cells, neuroblastoma, and coronaviruses including SARS-CoV-2 variants. XL177A is mainly used in studies related to colorectal cancer, neuroblastoma, and coronavirus infections.
    XL177A (GMP)
  • HY-W160358
    2,5-Dimethylcyclohexanol
    		Inhibitor 99.88%
    2,5-Dimethylcyclohexanol, a volatile organic compound, is a fatty acid that can be isolated from Amphora sp.. 2,5-Dimethylcyclohexanol has significant antineoplastic and antiviral activities with inhibition of SARS-CoV-2 Mpro. 2,5-Dimethylcyclohexanol also has potent antifungal activity against Pseudogymnoascus destructans. 2,5-Dimethylcyclohexanol compromises cell wall and membrane integrity while perturbing energy metabolism, increases the levels of ROS, ATP, Superoxide anion and GSH, and decreases CAT and SOD activities. And 2,5-Dimethylcyclohexanol alters virulence ribosomal genes expression, and disrupts the MAPK signaling pathways, inducing fungal cell apoptosis.
    2,5-Dimethylcyclohexanol
Cat. No. Product Name / Synonyms Species Source